American Airlines and Citi Launch the Citi / AAdvantage Globe Mastercard
Mid-Tier Credit Card Enhances Travel With Access to Premium Benefits Highlights: American Airlines, Citi and Mastercard launched a new mid-tier travel rewards credit... Read more.
Ivonescimab with Chemotherapy Reduced the Risk of Disease Progression or Death by 40% Compared to Tislelizumab (PD-1 Inhibitor) Plus Chemotherapy in 1L Treatment of Patients with Squamous NSCLC in the HARMONi-6 Study Conducted by Akeso in China
Ivonescimab in Combination with Chemotherapy Is the First Known Regimen to Achieve a Clinically Meaningful Benefit over an anti-PD-(L)1 Antibody Combined with Chemotherapy... Read more.
DS-3939 Shows Promising Preliminary Clinical Activity in Patients with Advanced Solid Tumors in Phase 1/2 Trial
First presentation of clinical data from the sixth DXd antibody drug conjugate from the oncology pipeline of Daiichi Sankyo Early results support continued development... Read more.
Raludotatug Deruxtecan Demonstrated Clinically Meaningful Response Rates in Patients with Recurrent Platinum-Resistant Ovarian, Primary Peritoneal or Fallopian Tube Cancer in Phase 2 Part of REJOICE-Ovarian01 Phase 2/3 Trial
An objective response rate of 50.5% was observed with raludotatug deruxtecan across all dose levels in these patients in the phase 2 part of REJOICE-Ovarian01 Phase... Read more.
Gilead to Spotlight New Virology Data Across HIV, Viral Hepatitis and Respiratory Diseases at IDWeek 2025
– Additional Phase 3 PURPOSE Data Reinforce the Safety Profile of Twice-Yearly Yeztugo® as an Effective HIV Prevention Option Across Diverse Populations – –... Read more.
DATROWAY® (datopotamab deruxtecan-dlnk) demonstrated unprecedented median overall survival improvement of five months vs. chemo as 1st-line treatment for patients with metastatic triple-negative breast cancer for whom immunotherapy was not an option
AstraZeneca and Daiichi Sankyo’s DATROWAY also demonstrated a highly statistically significant and clinically meaningful 43% reduction in patients’ risk of disease... Read more.
Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment
New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant... Read more.
ESMO 2025: Faeth Therapeutics’ Phase 2 DICE Trial Shows 34% Reduction in Risk of Disease Progression with Oral Sapanisertib Plus Chemotherapy
Randomized phase 2 study in platinum-resistant ovarian cancer met its prespecified hazard ratio target and primary endpoint, supporting advancement to phase 3; combination... Read more.
XTANDI® Plus Leuprolide Reduced Risk of Death by 40% vs Leuprolide Alone in Men with a Type of Advanced Prostate Cancer
The probability of survival at 8 years was an unprecedented 78.9% with XTANDI plus leuprolide versus 69.5% with leuprolide, in men with non-metastatic hormone-sensitive... Read more.
Tubulis Presents First Clinical Data from Phase I/IIa Trial for TUB-040 in Platinum-Resistant Ovarian Cancer (PROC) at ESMO 2025
TUB-040 demonstrated robust clinical activity with a favorable safety profile and excellent tolerability in biomarker-unselected, heavily pre-treated PROC patients... Read more.